Search

EHA at ICH meeting: Excessive bureaucracy harms patient safety and innovation

To solicit input from a wide range of non-ICH members about the revision of ICH E8(R1), ICH held a Public Meeting on ICH E8(R1) “General Considerations for Clinical Studies” (Silver Spring, USA, October 31, 2019).

Read more

Without access to treatment, can we truly innovate in rare diseases?

Interview with Giampaolo Merlini

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.

Read more

Blog

Life in hematology is exciting and poses many challenges, rewards and surprises. Follow our blog and be entertained, informed and inspired!

Read more

Meet Gert Ossenkoppele, our Volunteer of the Month

Can you tell us what you do for EHA and when you started? How did you became a volunteer? Who helped/encouraged you to become one?
I am lucky to be one of the first members of the EHA (member number 34).…

Read more

Meet Gert Ossenkoppele, our Volunteer of the Month

Can you tell us what you do for EHA and when you started? How did you became a volunteer? Who helped/encouraged you to become one?
I am lucky to be one of the first members of the EHA (member number 34).…

Read more

Advocacy priorities

The European Union works on countless pieces of legislation and policies that affect the health ecosystem. Some are relevant to most medical disciplines, including hematology—such as the legislation on health data or pharmaceuticals.

Read more

Hematology and oncology, pacemakers for EU HTA

EHA’s Martin Kaiser, right, addressing his fellow panelists. Left to right: Brian Cuffel (Bayer), Caroline Pothet (EMA), Roisin Adams (HTA CG), Bernhard Wörmann (DGHO) and Elisabeth de Vries (ESMO).

Read more